HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.

Abstract
Human immunodeficiency virus protease inhibitors (HIV-PIs), such as indinavir and saquinavir, have been shown to block angiogenesis and tumor cell invasion and to induce tumor cell apoptosis and growth arrest, respectively, both in vitro and in vivo. These findings have suggested that HIV-PIs or their analogues can be used as antitumor drugs. To this regard, indinavir and saquinavir were assessed for their ability to inhibit in vivo the growth of highly prevalent human tumors, such as lung, breast, colon and hepatic adenocarcinomas. We show here that both HIV-PIs significantly inhibited the growth of all adenocarcinomas tested in the mice model. This was not mediated by effects on proteasome-dependent cell growth arrest or on apoptosis but by the block of angiogenesis and matrix metalloproteinase activity. Accordingly, therapeutic steadystate concentrations of indinavir or saquinavir were highly effective in inhibiting invasion of tumor cells in vitro. In contrast, growth arrest was induced only by high concentrations of saquinavir that are not reached or are only transiently present in plasma of treated patients, likely through a proteasome-mediated mechanism. These data suggest that HIV-PIs or their analogues, characterized by a better biodistribution and lower toxicity, may represent a new class of antitumor drugs capable of targeting both matrix metalloproteinases and the proteasome for a most effective antitumor therapy.
AuthorsElena Toschi, Cecilia Sgadari, Laura Malavasi, Ilaria Bacigalupo, Chiara Chiozzini, Davide Carlei, Daniela Compagnoni, Stefania Bellino, Roberto Bugarini, Mario Falchi, Clelia Palladino, Patrizia Leone, Giovanni Barillari, Paolo Monini, Barbara Ensoli
JournalInternational journal of cancer (Int J Cancer) Vol. 128 Issue 1 Pg. 82-93 (Jan 01 2011) ISSN: 1097-0215 [Electronic] United States
PMID20617515 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 UICC.
Chemical References
  • HIV Protease Inhibitors
  • Matrix Metalloproteinase Inhibitors
  • Indinavir
  • Matrix Metalloproteinases
  • Matrix Metalloproteinase 2
  • Proteasome Endopeptidase Complex
  • Saquinavir
Topics
  • Animals
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Dose-Response Relationship, Drug
  • Female
  • HIV Protease Inhibitors (pharmacology)
  • Humans
  • Immunohistochemistry
  • Indinavir (pharmacology)
  • Matrix Metalloproteinase 2 (metabolism)
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases (metabolism)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasms (blood supply, pathology, prevention & control)
  • Neovascularization, Pathologic (metabolism, prevention & control)
  • Proteasome Endopeptidase Complex (metabolism)
  • Saquinavir (pharmacology)
  • Tumor Burden (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: